Paclitaxel as neoadjuvant therapy for high grade angiosarcoma of the spleen: A brief report and literature review

Clinical Medicine Insights: Oncology

Volumn 4, Issue , 2010, Pages 107-110

  Vakkalanka, Bhanu ^a   Milhem, Mohammed ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Angiosarcoma; Paclitaxel; Sarcoma; Spleen

Indexed keywords

PACLITAXEL;

ADVANCED CANCER; AGED; ANGIOSARCOMA; ARTICLE; BONE SCINTISCANNING; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECT; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; INOPERABLE CANCER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEURA EFFUSION; SPLEEN CANCER; SPLENOMEGALY; SYSTEMIC DISEASE;

EID: 78649343977     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S5329     Document Type: Article

References (21)

1. Falk S, Krishnan J, Meis JM. Primary angiosarcoma of the spleen. A clinicopathologic study of 40 cases. Am J Surg Pathol. 1993;17(10): 959-70.
2. Langhans T. Pulsating cavernous neoplasm of the spleen with metastatic nodules to the liver. Virchows Arch Pathol Anat. 1879;75:273-91.
3. Neuhauser TS, Derringer GA, Thompson LD, et al. Splenic angiosarcoma: a clinicopathologic and immunophenotypic study of 28 cases. Mod Pathol. 2000;13(9):978-87.
4. Thompson WM, Levy AD, Aguilera NS, et al. Angiosarcoma of the spleen: imaging characteristics in 12 patients. Radiology. 2005;235(1):106-15.
5. Fayette J, Martin E, Piperno-Neumann S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol. 2007;18(12):2030-6.
6. Simon R, Bert H, Christian G, et al. Thrombocytopenia as first manifestation of splenic angiosarcoma. Ann Hematol. 2010;89(1):109-10.
7. Abraham JA, Hornicek FJ, Kaufman AM, et al. Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol. 2007;14(6):1953-67.
8. Lahat G, Dhuka AR, Lahat S, et al. Outcome of locally recurrent and metastatic angiosarcoma. Ann Surg Oncol. 2009;16(9):2502-9.
9. Wilson R, Glaros S, Brown RK, et al. Complete radiographic response of primary pulmonary angiosarcomas following gemcitabine and taxotere. Lung Cancer. 2008;61(1):131-6.
10. Asmane I, Litique V, Heymann S, et al. Adriamycin, cisplatin, ifosfamide and paclitaxel combination as front-line chemotherapy for locally advanced and metastatic angiosarcoma. Analysis of three case reports and review of the literature. Anticancer Res. 2008;28(5B):3041-5.
11. Rowinsky EK. Antimicrotubule agents. Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy: principles and practice, 4th ed. Philadelphia: Lippincot Williams & Wilkins, 2005:237.
12. Foa R, Norton L, Seidman AD. Taxol (paclitaxel) a novel micro-tubule agent with remarkable anti-neoplastic activity. Int J Clin Lab Res. 1994;24(1):6-14.
13. Jordan MA, Toso RJ, Thrower D, et al. Mechanism of mitotic block and inhibition cell proliferation by Taxol at low concentrations. Proc Natl Acad Sci U S A. 1993;90(20):9552-6.
14. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996;2(11):1843-9.
15. Casper ES, Waltzman R, Schwartz G, et al. Phase II study of paclitaxel in sarcoma. CancerInvest 1998;16:442-6.
16. Fata F, O'Reilly E, Ilson D, Pfister D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999;86(10): 2034-7.
17. Penel N, Bui BN, Bay JO, Cupissol D, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008;26(32):5269-74.
18. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
19. Stebbing J, Wildfire A, Portsmouth S, et al. Paclitaxel for anthracycline- resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations. Ann Oncol. 2003;14(11):1660-6.
20. Goodman and Gillman's The pharmacological basis of therapeutics. 11th edition (2006). Brunton LL ed. The McGraw-Hill Companies, Inc. Chapter 51: Antineoplastic agents.Antimitiotic agents.Taxanes.
21. Tulpule A, Groopman J, Saville MW, et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer. 2002;95(1):147-54.